SCHEMBL6551089

SCHEMBL6551089

COc1nn(-c2ccc(C(N)=O)cc2)c(=O)o1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABHD16A O95870 2/20 0.67
LPL P06858 1/20 0.61
LIPC P11150 1/20 0.61
LIPE Q05469 1/20 0.61
MGLL Q99685 3/20 0.60
FAAH O00519 3/20 0.60
ALDH1A1 P00352 2/20 0.46
MAPKAPK2 P49137 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
PARP1 P09874 1/20 0.45
PARP10 Q53GL7 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
PARP4 Q9UKK3 1/20 0.45
ABHD6 Q9BV23 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601668 0.84 ABHD16A (0.54) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL7046228 0.83 ABHD16A (0.72) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL2233598 0.80 ABHD16A (0.72) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL2233406 0.80 ABHD16A (0.72) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL11620781 0.80 FAAH (0.78) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL6551854 0.78 FAAH (0.74) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL7047919 0.77 LPL (1.00) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL2237968 0.75 ABHD16A (0.72) ABHD16ALPLLIPCLIPEMGLL
SCHEMBL6552566 0.75 MGLL (1.00) ABHD16AMGLLFAAH
SCHEMBL7044266 0.75 LPL (0.70) ABHD16ALPLLIPCLIPEMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482929-A1 USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE Aventis Pharma Deutschland GmbH (DE) 2004-12-08 EP disclosed
EP-1263745-B1 SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE AVENTIS PHARMA GMBH (DE) 2004-05-19 EP disclosed
WO-2003072098-A1 USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-04 WO disclosed
EP-1263745-A1 SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE Aventis Pharma Deutschland GmbH (DE) 2002-12-11 EP disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
WO-2001066531-A1 SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONE AND USE THEREOF FOR INHIBITING HORMONE-SENSITIVE LIPASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-09-13 WO disclosed